4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
SAB Biotherapeutics, Inc. (SABS) operates in the Biotechnology industry and is headquartered in Miami Beach, United States with about 86 employees. Its market capitalization is roughly $303 million. In the fiscal year ended 2025-12-31, SABS reported $0M in revenue and $13M in net income.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($49M) | ($43M) | ($38M) | ($29M) | — |
| Net Income | $13M | ($34M) | ($42M) | ($19M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($20M) | ($16M) | ($13M) | ($10M) | ($11M) | — |
| Net Income | ($19M) | ($17M) | $45M | ($10M) | ($5M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $173M | $44M | $84M | $51M | — |
| Total Liabilities | $21M | $18M | $27M | $20M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SABS viewer.
About TickerBase · Data methodology & sources